Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

Date : 09/03/2019 @ 3:30PM
Source : GlobeNewswire Inc.
Stock : Zynerba Pharmaceuticals Inc (ZYNE)
Quote : 5.7  -0.32 (-5.32%) @ 4:59AM
After Hours
Last Trade
Last $ 5.86 ▲ 0.16 (2.81%)

Zynerba Pharmaceuticals to Present at Two Upcoming Conferences

Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart

6 Months : From Jul 2019 to Jan 2020

Click Here for more Zynerba Pharmaceuticals Charts.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at two upcoming conferences in New York City.

  • The HC Wainwright 21st Annual Healthcare conference on Monday September 9, 2019 at 9:10AM EDT at the Lotte New York Palace Hotel; and
  • The Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 2:30PM EDT at the Sofitel Hotel.

A live webcast of the presentations will be accessible on the Investor Relations page of http://www.zynerba.com. A replay of the webcasts will be available for 90 days following the conclusion of the event.

About Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 Deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.  

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations.  These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Investor ContactWilliam Roberts, Vice President, Investor Relations and Corporate CommunicationsZynerba Pharmaceuticals484.581.7489 robertsw@zynerba.com

Latest ZYNE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.